Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EFZO-FIT Phase 3 Pulmonary Sarcoidosis Trial (Japan)
jRCT2011220021Phase 3Active, not recruiting
- Sponsor
- Kyorin Pharmaceutical
- Start
- Jan 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of efzofitimod in pulmonary sarcoidosis (3 arms), sponsored by Kyorin Pharmaceutical. Primary endpoint: Change from baseline in mean daily oral corticosteroid (OCS) dose post-taper. Started Jan 2023; status: active, not recruiting.
02
Drugs
efzofitimod
03
Conditions
pulmonary sarcoidosis
Beyond the preview
Go deeper on jRCT2011220021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011220021.